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cervix was performed, and neuroendocrine carcinoma of the uterine
cervix was observed (suspected small cell carcinoma).
An immunohistochemical study revealed that the tumor cells were
immunoreactive for synaptophysin, chromogranin A, CK7, CK20, and
CK CAM5.2. They were negative for CD56, CK5/6, and CK 34βE12.
Magnetic resonance imaging revealed a focal tumor of the cervix
with a contrast effect, a submucosal uterine myoma, and no obvious
disease outside the uterus (Fig. 1a). In addition, ﬂuorodeoxyglucose
positron emission tomography/computed tomography (PET/CT)Background
Neuroendocrine tumors of the uterine cervix are rare, accounting
for less than 5% of cervical cancers (Albores-Saavedra et al., 1997;
Viswanathan et al., 2004). The etiology and clinicopathological features
of these neuroendocrine tumors remain unknown. A PubMed search
revealed only 14 previously reported cases of atypical carcinoid of the
uterine cervix in the literature, and the clinical course of many of
them is unknown (Boruta et al., 2001; Gilks et al., 1997; Koch et al.,
1999; McCusker et al., 2003; Wang et al., 2006; Wistuba et al., 1999).
A recent consensus conference suggested four general categories of
neuroendocrine tumors of the uterine cervix, analogous to pulmonary
neuroendocrine tumors: typical and atypical carcinoid tumors, large
cell neuroendocrine carcinomas, and small cell carcinomas (Albores-
Saavedra et al., 1997).
We herein report a case of International Federation of Gynecology
and Obstetrics (FIGO) stage IB2 atypical carcinoid of the uterine cervix
with aggressive clinical behavior.
Case
A 44-year-old Japanese woman (gravid 2, para 2) had abnormal
Pap smear results. There was nothing noteworthy in her family or
medical histories. There were no abnormalities of the vaginal wall orrics and Gynecology, Ehime
n, Ehime 791-0295, Japan. Fax:
a).
c. Open access under CC BY-NC-ND license. scanning demonstrated the absence of a metastatic lesion outside the
uterus and the presence of high FDG uptake within the cervix (Fig. 1b).
The patient was diagnosed with stage IB2 advanced cervical cancer
according to the 2008 FIGO criteria. Routine laboratory tests and
serum squamous cell antigen, carcinoembryonic antigen, carbohydrate
antigen (CA)19-9, CA125, CA72-4, and neuron-speciﬁc enolase were
within normal limits.
After the diagnosis was made, radical hysterectomy with systemic
pelvic lymph node dissection and bilateral salpingo-oophorectomy
were performed. The uterus in the modiﬁed radical hysterectomy
specimen showed a 40× 55-mm tumor localized to the uterine cervix
(Fig. 2). Cytologically, the tumor mostly comprised ovoid to columnar
cells of various sizes. The cells had relatively abundant cytoplasm, oval
nuclear pleomorphism, and irregularity. Histology of the lesion revealed
that the tumor focally extended into the stroma with palisading of
columnar cells and rosette-like structures. Increased mitotic activity
(1–5 mitotic ﬁgures in every 10 high-power ﬁelds) was seen within
the tumors (Fig. 3a).
An immunohistochemical study was performed. Most tumor cells
were strongly positive for chromogranin A and synaptophysin. 75% of
the cells were positive for Ki-67/MIB-1 (Fig. 3b–d). Lymphovascular
invasion was evident. No metastases were found in the 63 resected
lymph nodes (pT1B2N0M0). The combination of the hematoxylin–
eosin morphologic ﬁndings and immunohistochemical expression
proﬁle conﬁrmed the diagnosis of an atypical carcinoid tumor of the
uterine cervix.
Following the operation, the patient underwent adjuvant-combined
chemotherapy with CPT-11 + cisplatin (CPT-11 at 60 mg/m2 was
administered intravenously on days 1, 8, and 15 in combination with
cisplatin at 60 mg/m2 on day 1) over 4 weeks and was followed-up.
Four months after the chemotherapy, the patient complained of back
pain, and CT demonstrated hydronephrosis of both kidneys secondary
to a recurrent tumor around the ureteral oriﬁce. In addition, PET/CT
revealed hydronephrosis and a recurrent tumor around the pelvic
Fig. 1. (a) Preoperative pelvic magnetic resonance imaging revealed a focal tumor of the
cervix with a contrast effect. (b) Fluorodeoxyglucose positron emission tomography/
computed tomography scanningdemonstratedhighﬂuorodeoxyglucose uptake in the cervix.
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Bilateral nephrostomies were thus established. As second-line
chemotherapy, the patient underwent three courses of the TC regimen
(paclitaxel at 175mg/m2+CBDCA 5AUC). She subsequently developed
severe abdominal and perineal pain and ileus after three courses of the
monthly TC regimen. Dietary intake became difﬁcult. She died of the
disease 13months after the initial operation.
Discussion
A recent consensus conference suggested four general categories of
neuroendocrine tumors of the uterine cervix, analogous to pulmonary
neuroendocrine tumors: typical and atypical carcinoid tumors, large
cell neuroendocrine carcinomas, and small cell carcinomas (Albores-
Saavedra et al., 1997). Among these categories, the incidence of smallFig. 2.Macroscopic ﬁndings of the surgical specimen.cell neuroendocrine carcinoma is the highest, accounting for about
80% of all cases; the other subtypes are rare. Human papillomavirus
type 18 was found in 40% of cases of one series, whereas type 16 was
found in only 28% (Albores-Saavedra et al., 1997).
Clinically, neuroendocrine carcinomas account for less than 5% of all
cervical carcinomas. Neuroendocrine tumors of the cervix are
characterized by a younger patient age at onset (Savorgaonkar et al.,
1996), earlier distant metastasis, and a worse prognosis compared
with other histological types. While most patients have a low-stage
tumor at the time of diagnosis, the outlook is poor nonetheless.
Walker et al. (1988) reported that 75% of patients die within 1year.
Carcinoid tumors can occur systemically and have been reported in
the lung, pancreas, gastrointestinal tract, and thyroid. Albores-Saavedra
et al. (1972) was the ﬁrst to report an atypical carcinoid of the uterine
cervix. Since then, the etiology and clinicopathological features have
remained unknown because of the rarity of these tumors. Among the
carcinomas of the cervix with neuroendocrine differentiation, small cell
carcinomas are well characterized (Gilks et al., 1997). Non-small cell
neuroendocrine carcinomas of the uterine cervix, however, have rarely
been described and are probably underdiagnosed or misdiagnosed
(Albores-Saavedra et al., 1976, 1979; Park et al., 2011). Immunohisto-
chemical studies including synaptophysin and chromogranin A are useful
for detecting neuroendocrine differentiation, and strong Ki-67/MIB-1
labeling indicates the malignant characteristics of neuroendocrine
tumors.
The therapy for neuroendocrine carcinoma of the uterine cervix
remains controversial because of the rarity of these tumors. Although
various chemotherapeutic regimens have been tried, none is associated
with a good response. In recent years, novel treatment approaches to
small cell carcinoma of the cervix have attempted to replicate successful
treatments for small cell carcinoma of the lung. Therefore, patients with
neuroendocrine carcinoma of the cervix tend to receive combination
chemotherapy comprising etoposide + cisplatin (Boruta et al., 2001;
Chang et al., 1998; Hoskins et al., 2003) or CPT-11 + cisplatin in
accordance with the standard chemotherapy for primary small cell lung
cancer (Noda et al., 2002). However, there is no evidence of treatment
speciﬁc to other subtypes of neuroendocrine tumors of the cervix,
including atypical carcinoids. The success of concurrent chemoradiation
for other types of locally advanced cervical cancer has also inﬂuenced
the management of neuroendocrine carcinoma of the cervix.
Several case reports and small case series involving patients with
small cell carcinoma of the uterine cervix have indicated encouraging
outcomes in patients treated with a combination of radical hysterectomy
or radiation therapy and chemotherapy. However, the numbers of
patients and follow-up periods have been insufﬁcient to determine
whether chemotherapy can improve the outcome of patients with small
cell carcinoma of the cervix (Boruta et al., 2001; Lee et al., 2008;
McCusker et al., 2003; Viswanathan et al., 2004; Wang et al., 2006).
A PubMed search revealed only 14 previously reported cases of
atypical carcinoid of the uterine cervix, and the clinical course of many
of them is unknown (Boruta et al., 2001; Gilks et al., 1997; Koch et al.,
1999; McCusker et al., 2003; Wang et al., 2006; Wistuba et al., 1999).
In our case, because it was expected that radiation therapy is not
effective in carcinoid tumors (Louka et al., 1982), the patient was treated
with adjuvant chemotherapy alone. Tangjitgamol et al. (2007) reported
good results with the TC regimen against large cell neuroendocrine
carcinomas. Therefore, our patient was treated with this regimen after
her recurrence, but the tumor progression was not suppressed. After
her recurrence, she did not wish to undergo radiotherapy.
Hoskins et al. (2003) reported encouraging results using concurrent
chemoradiation in patients with advanced disease. Routine inclusion of
para-aortic irradiation in their protocol resulted in a 3-year survival
rate of 60% and failure-free survival rate of 57%. Viswanathan
(Viswanathan et al., 2004) reported that the probability of recurrence
within the radiation ﬁelds is low (only 2 of 15 patients) among patients
who were treated with radiation therapy. Inclusion of concurrent
6 T. Yasuoka et al. / Gynecologic Oncology Reports 7 (2014) 4–6chemoradiation after radical hysterectomy may improve the results of
combined-modality treatment similar to small cell carcinoma, even
atypical carcinoid.
In conclusion, we have reported a case of an atypical carcinoid of the
uterine cervixwith resistance to CPT-11+cisplatin and TC chemotherapy
and strongKi-67/MIB-1 labeling. Because of the rarity of atypical carcinoid
of the uterine cervix, it may be extremely difﬁcult establish a standard
treatment by performing randomized controlled trials.
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